An Overview of the Cardioprotective Effects of Novel Antidiabetic Classes: Focus on Inflammation, Oxidative Stress, and Fibrosis
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24097789 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Dora Bianka Balogh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Center, MTA Center of Excellence, Semmelweis University, 1085 Budapest, Hungary. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Cardiovascular Diseases. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: New National Excellence Program of The Ministry for Culture and Innovation from the source of the National Research, Development and Innovation Fund, Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, New National Excellence Program of The Ministry for Culture and Innovation.
Abstract (Originalsprache)
Metabolic diseases, particularly diabetes mellitus (DM), are significant global public health concerns. Despite the widespread use of standard-of-care therapies, cardiovascular disease (CVD) remains the leading cause of death among diabetic patients. Early and evidence-based interventions to reduce CVD are urgently needed. Large clinical trials have recently shown that sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) ameliorate adverse cardiorenal outcomes in patients with type 2 DM. These quite unexpected positive results represent a paradigm shift in type 2 DM management, from the sole importance of glycemic control to the simultaneous improvement of cardiovascular outcomes. Moreover, SGLT2i is also found to be cardio- and nephroprotective in non-diabetic patients. Several mechanisms, which may be potentially independent or at least separate from the reduction in blood glucose levels, have already been identified behind the beneficial effect of these drugs. However, there is still much to be understood regarding the exact pathomechanisms. This review provides an overview of the current literature and sheds light on the modes of action of novel antidiabetic drugs, focusing on inflammation, oxidative stress, and fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Center, MTA Center of Excellence, Semmelweis University, 1085 Budapest, Hungary.
- MTA-SE Lendület "Momentum" Diabetes Research Group, 1083 Budapest, Hungary.
- Department of Surgery, Transplantation, and Gastroenterology, Semmelweis University, 1085 Budapest, Hungary.
ORCID-Profile: Dora Bianka Balogh, Laszlo Jozsef Wagner
Förderung
- New National Excellence Program of The Ministry for Culture and Innovation from the source of the National Research, Development and Innovation Fund
- Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund
- New National Excellence Program of The Ministry for Culture and Innovation
- Ministry of Innovation and Technology of Hungary
Zitieren
APA
Balogh, D. B., Wagner, L. J., & Fekete, A. (2023). An Overview of the Cardioprotective Effects of Novel Antidiabetic Classes: Focus on Inflammation, Oxidative Stress, and Fibrosis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24097789
Vancouver
Balogh DB, Wagner LJ, Fekete A. An Overview of the Cardioprotective Effects of Novel Antidiabetic Classes: Focus on Inflammation, Oxidative Stress, and Fibrosis. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24097789
BibTeX
@article{Balogh2023,
author = {Balogh, Dora Bianka and Wagner, Laszlo Jozsef and Fekete, Andrea},
title = {An Overview of the Cardioprotective Effects of Novel Antidiabetic Classes: Focus on Inflammation, Oxidative Stress, and Fibrosis},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24097789}
}
EUVIMED